New combo aims to stall lung cancer in patients with tough gene mutation
NCT ID NCT07554339
First seen May 05, 2026 · Last updated May 05, 2026
Summary
This study tests whether adding the targeted drug MK-1084 to the immunotherapy durvalumab helps people with a specific type of advanced lung cancer (KRAS G12C mutation) live longer without their cancer growing. About 310 adults who have finished chemotherapy and radiation without their cancer getting worse will receive either the drug combo or a placebo plus durvalumab. The goal is to see if the new combination can better control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.